Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sequenom Fires CEO And Research Executive

by Ann M. Thayer
October 5, 2009 | A version of this story appeared in Volume 87, Issue 40

Sequenom has ousted its president and CEO, Harry Stylli, and senior vice president of R&D, Elizabeth Dragon. The dismissals follow an independent investigation that found data and results related to the development of the company’s Trisomy 21 (Down syndrome) prenatal test included unsubstantiated claims, inconsistencies, and errors. Deficiencies in disclosure controls and procedures led to public reports of the data and results. The company also has obtained the resignations of its chief financial officer and another officer, and it has fired three other employees.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.